[{"id":"11f39916-f846-4abd-84f2-ab962404b17d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04353830","created_at":"2021-07-05T07:53:20.350Z","updated_at":"2024-07-02T16:35:54.425Z","phase":"Phase 1a","brief_title":"A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors","source_id_and_acronym":"NCT04353830","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" TIGIT","pipe":"","alterations":" ","tags":["TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • tamgiblimab (IBI-939)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/22/2020","start_date":" 05/22/2020","primary_txt":" Primary completion: 05/11/2022","primary_completion_date":" 05/11/2022","study_txt":" Completion: 05/11/2022","study_completion_date":" 05/11/2022","last_update_posted":"2023-03-01"}]